1. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP (1998) Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 32: 35-41
2. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99: 1540-7
3. Anderson JL, Muhlestein JB (2000) The ACADEMIC study in perspective (Azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia). J Infect Dis 181: 569-71
4. Bartels C, Maass M, Bein G, Malisius R, Brill N, Bechtel JF, Sayk (1999) Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 99: 879-82
5. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.
Circulation 99: 855-60
6. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P (2003) Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndromes in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial.
Lancet 361: 809-813
7. Chatzimanolis EM, Lefatzis D; Pavlopoulos A (1998) Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother 41: 81-84
8. Chiu B, Viira E, Tucker W, Fong IW (1997) Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 96: 2144-8
9. Choussat R, Montalescot G, Collet J, Jardel C, Ankri A, Fillet A, Thomas D, Raymond J, Bastard J, Drobinski G, Orfila J, Agut H (2000) Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol 86:
379-84
10. Cook PJ, Lip GY, Davies P, Beevers DG, Wise R, Honeybourne D (1998) Chlamydia pneumoniae antibodies in severe essential hypertension.
Hypertension 31: 589-94
43
11. Dahlen GH, Boman J, Birgander LS, Lindblom B (1995) Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 114: 165-74
12. Danesh J, Collins R, Peto R (1997) Chronic infections and coronary heart disease: is there a link? Lancet 350: 430-6
13. Danesh J, Wong Y, Ward M, Muir J (1999) Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart 81: 245-7
14. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB (2000) Low grade inflammation and coronary heart disease:
prospective study and updated meta-analyses. BMJ 321: 199-204
15. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Wong Y, Bernardes-Silva M, Ward M (2000) Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 321: 208-13 16. Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thomson A, Wong
YK, Zhou X, Ward M (2002) Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 23: 371-5
17. DeStefano F, Merritt RK, Anda RF, Casper ML, Eaker ED (1993) Trends in nonfatal coronary heart disease in the United States, 1980 through 1989. Arch Intern Med 153: 2489-2494
18. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC (1999) Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100:
1369-73
19. Dunne MW (1999) WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. Am Heart J 138: S542-4
20. Dunne MW (2000) Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 181 Suppl 3: S572-8
21. Epstein S, Jianhui Z (1999) Lack of association of infectious agents with risk of future myocardial infarction and stroke. Circulation 100: 1366-1368
22. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J (2000) Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke 31: 2127-33 23. Ewald PW, Cochran GM (2000) Chlamydia pneumoniae and cardiovascular
disease: an evolutionary perspective on infectious causation and antibiotic treatment. J Infect Dis 181 Suppl 3: S394-401
24. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, Kes S, Tokgozoglu L (2000) Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 38: 4408-11
44
25. Fong IW (2000) Emerging relations between infectious diseases and coronary artery disease. CMAJ 163: 49-56
26. Frothingham C (1911) The relationship between acute infectious diseases and arterial lesions. Arch Intern Med. 8: 153-162
27. Gabay MP, Jain R (2002) Role of antibiotics for the prevention of cardiovascular disease. Ann Pharmacother 36: 1629-36
28. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC (1996) Replication of Chlamydia pneumoniae in vitro in human macrophages. Infect Immun 64: 1614-20
29. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA; Solbach W, Maass M (2001) Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103: 351-356
30. Godzik KL, O'Brien ER, Wang SK, Kuo CC (1995) In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 33: 2411-4
31. Grayston JT (1998) Antibiotic treatment of C. pneumoniae for secondary prevention of cardiovascular events. Circulation 97: 1669-1670
32. Grayston JT (1992) Infections caused by Chlamydia pneumoniae strain TWAR.
Clin Infect Dis 165: 757-761
33. Grayston JT (1999) Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg 134: 930-4
34. Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA (1999) Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues. Am Heart J 138: 545-9
35. Grayston JT (2000) Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181 Suppl 3: S402-10
36. Grayston JT (2000) What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis? J Infect Dis 181 Suppl 3:
585-6
37. Grayston JT (2003) Antibiotic Treatment of Atherosclerotic Cardiovascular Disease. Circulation 107: 1228-1230
38. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96: 404-7 39. Gupta S (1999) Chronic infection in the aetiology of atherosclerosis--focus on
Chlamydia pneumoniae. Atherosclerosis 143: 1-6
40. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B (1997) Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study.
ROXIS Study Group. Lancet 350: 404-7
41. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20: 121-7
45
42. Hahn DL, Golubjatnikov R (1992) Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 12: 945-7
43. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349: 462-6
44. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS (1999) Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg. Infect. Dis. 5: 281-284
45. Kadota J (1996) Non-antibiotic effects of antibiotics. Clin Microbiol Infect 1:
2S20-2S22
46. Kähler J, Köster R, Braser JH, Schäfer P, Terres W, Hamm CW (1999) Bedeutung von Chlamydia pneumoniae in der Pathogenese der koronaren Herzerkrankung. Z Kardiol 88: 885-95
47. Kalayoglu MV, Byrne GI (1998) Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 177: 725-9
48. Kalayoglu MV, Libby P, Byrne GI (2002) Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288: 2724-31
49. Kanamoto Y, Ouchi K, Mizui M, Ushio M, Usui T (1991) Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan. J Clin Microbiol 29: 816-818
50. Kannel WB, Vokonas PS (1992) Demographics of the prevalence, incidence and management of coronary heart disease in the elderly and in women. Ann Epidemiol 2: 5-14
51. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P (1994) Chlamydia pneumoniae IgG antibody prevalence in south western and eastern Finland in 1982 and 1987. Int J Epidemiol 23: 176-184
52. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P (1994) Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 23: 1315-21
53. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M (1994) Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 16:
313-9
54. Kuo CC, Campbell LA (2000) Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 181: S432-6
55. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT (1993) Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167: 841-9
56. Kutlin A, Roblin PM, Hammerschlag MR (1999) In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 43: 2268-72
57. Leinonen M, Saikku P (2000) Infections and atherosclerosis. Scand Cardiovasc J 34: 12-20
46
58. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S (2001) Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84 Suppl 3: S669-75
59 Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P (1993) Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 87: 1130-4
60 Liu JL, Maniadakis N, Gray A, Rayner M (2002) The economic burden of coronary heart disease in the UK. Heart 88: 597-603
61. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-24
62. Luchsinger JA, Pablos-Mendez A, Knirsch C, Rabinowitz D, Shea S (2002) Relation of antibiotic use to risk of myocardial infarction in the general population. Am J Cardiol 89: 18-21
63. Maass M, Bartels C, Kruger S, Krause E, Engel PM, Dalhoff K (1998) Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 140 Suppl 1:
25-30
64. Mach F, Lovis C, Gaspoz JM, Unger PF, Bouillie M, Urban P; Rutishauser W (1997) C-reactive protein as a marker for acute coronary syndromes. Eur Heart J 18: 1897-1902
65. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H (1999) Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 100: 832-7
66. Martin D, Bursill J, Qui MR, Breit SN, Campbell T (1998) Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 351:
1858-9
67. Mazzoli S, Tofani N, Fantini A, Semplici F, Bandini F, Salvi A, Vergassola R (1998) Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 135: 15-20
68. Mehta JL, Saldeen TG, Rand K (1998) Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 31: 1217-25
69. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281: 427-431
70. Meier CR (2000) Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis 181: 558-62
71. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, Toosey T, Camm AJ, Northfield TC (1995) Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 30: 121-8 72. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC (1996) C reactive
protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312: 1061-5
47
73. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K, Laakso M (1996) Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 17: 682-8
74. Mira E, Benazzo M (2001) A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections:
comparison with amoxycillin/clavulanic acid. J Chemother 13: 621-7
75. Miyashita N, Toyota E, Sawayama T, Matsushima T (1998) An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan. Eur Heart J 19: 971
76. Moazed TC, Campbell LA, Rosendfeld ME, Grayston JT, Kuo CC (1999) Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 180: 238-241
77. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF (1998) Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97: 633-6
78. Muhlestein JB (2000) Chronic infection and coronary artery disease. Med Clin North Am 84: 123-148L
79. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102: 1755-60
80. Neumann FJ, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Jogethaei N, da Costa CP, Wagner H, Schomig A (2001) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357: 2085-9
81. Neumann FJ (2002) Chlamydia pneumoniae-atherosclerosis link: a sound concept in search for clinical relevance. Circulation 106: 2414-6
82. Odeh M, Oliven A (1992) Chlamydial infections of the heart. Eur J Clin Microbiol Infect Dis 11: 885-93
83. Osler W (1908) Diseases of the arteries. In W. Osler and T. MacCrae (ed.), Modern medicine: its theory and practice in original contributions by American and foreign authors . Lea & Febiger, Philadelphia, pp 426-447
84. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D (1998) Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not.
Epidemiol Infect 120: 93-9
85. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC, Mendall MA (1994) Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 343: 1634-5
86. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, et al. (1995) Association of
48
Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711-4
87. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jonsson B, Schwartz JS (1996) Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 93:1796-802
88. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979
89. Ridker PM (1998) Inflammation, infection, and cardiovascular risk. How good is the clinical evidence? Circulation 97: 1671-1674
90. Ridker PM. Kundesin RB, Stampfer MJ, Poulin S, Hennekens CH (1999) Prospective Study of Chlamydia pneumoniae IgG Seropositivity and Risks of Future Myocardial Infarction. Circulation 99: 1161-4
91. Rosen H, Muhlestein J, Bartlett J, Chen S, Chikami G, Corson M, Shah PK, Gurfinkel E, Handsfield H, Jackson L, Knirsch C, Kronmal R; McCutchan JA, Shea S (2000) Collaborative multidisciplinary workshop report: Clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease. J Infect Dis 181: 582-4
92. Ross R (1999) Atherosclerosis - An Inflammatory Disease. N Engl J Med 340:
115-126
93. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD; Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-9
94. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2: 983-986.
95. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B (2002) Reduced progression of early carotid atherosclerosis after antibiotic treatment and C.
pneumoniae seropositivity. Circulation 106(19): 2428-2433
96. Scaglione F, Rossoni G (1998) Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrobial Chemother 41:
47-50
97. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS (2002) Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non–Q-Wave Coronary Syndrome.
Circulation 105: 1555-1560
98. Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, Psaty BM, Tracy RP, Kuller LH, Kronmal RA (2000) Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study. Circulation 102: 2335-40
49
99. Stille W, Dittmann R (1998) Arteriosklerose als Folge einer chronischen Infektion durch Chlamydia pneumoniae. Herz 23: 185-92
100. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:
1219-23
101. Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, Weiss NS (1991) Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 11:
547-51
102. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR (1992) Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268: 68-72
103. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, Corea L (1999) C-Reactive Protein as a Marker for Cardiac Ischemic Events in the Year After a First, Uncomplicated Myocardial Infarction. Am J Cardiol 83:
1595-1599
104. Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F, Bertinieri G, Tien TV, Ceriani G, Tarsia P, Arosio C, Ranzi ML (1999) Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 99: 1555-1559
105. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L (1998) Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 19: 570-7 106. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N,
Shani J, Frankel R, Penney K, Quinn TC, Hammerschlag MR, Schachter J (1996) Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 173: 957-62
107. Wiesli P, Czerwenka W, Meniconi A, Maly FE, Hoffmann U, Vetter W, Schulthess G (2002) Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation 105:
2646-52
108. Wong Y, Ward ME (1999) Chlamydia pneumoniae and atherosclerosis. J Clin Pathol 52: 398-9
109. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, Gottwik M, Altmann E, Seidel F, Rox J, Hoffler U, Neuhaus KL, Senges J (2003) Antibiotic therapy after acute myocardial infarction: a prospective randomized study.
Circulation 107: 1253-9
50